With its acquisition of Encode, Bennu has obtained intellectual property rights related to EC Cysteamine, including an exclusive worldwide license to develop and market a product which has received orphan status.
EC Cysteamine is a proprietary enterically coated formulation of cysteamine bitartrate, a cystine depleting agent currently approved by the FDA. Cysteamine bitartrate is prescribed for the management of the genetic disorder known as nephropathic cystinosis.
Christopher Starr, Raptor’s CEO, said: “EC Cysteamine will add value, and balance our clinical portfolio with an advanced clinical program focused on a safe and potentially more effective second-generation, proprietary treatment for the management of cystinosis. We plan to continue evaluating EC Cysteamine in other disorders for which it has already shown promise in the clinic.”